90 related articles for article (PubMed ID: 16755333)
1. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
Urbano N; Papi S; Ginanneschi M; De Santis R; Pace S; Lindstedt R; Ferrari L; Choi S; Paganelli G; Chinol M
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):68-77. PubMed ID: 16755333
[TBL] [Abstract][Full Text] [Related]
2. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.
Axworthy DB; Reno JM; Hylarides MD; Mallett RW; Theodore LJ; Gustavson LM; Su F; Hobson LJ; Beaumier PL; Fritzberg AR
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1802-7. PubMed ID: 10677537
[TBL] [Abstract][Full Text] [Related]
3. Pretargeting: A Path Forward for Radioimmunotherapy.
Cheal SM; Chung SK; Vaughn BA; Cheung NV; Larson SM
J Nucl Med; 2022 Sep; 63(9):1302-1315. PubMed ID: 36215514
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Applications of Pretargeting.
Verhoeven M; Seimbille Y; Dalm SU
Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31480515
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of a truncated tissue factor‑coagulation‑based composite system for selective thrombosis in tumor blood vessels.
Xu P; Zou M; Wang S; Li T; Liu C; Wang L; Wang L; Luo F; Wu T; Yan J
Int J Oncol; 2019 Oct; 55(4):823-832. PubMed ID: 31432158
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer.
Vesci L; Carollo V; Rosi A; De Santis R
Oncol Lett; 2019 Mar; 17(3):3529-3536. PubMed ID: 30867794
[TBL] [Abstract][Full Text] [Related]
7. AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies.
Milazzo FM; Anastasi AM; Chiapparino C; Rosi A; Leoni B; Vesci L; Petronzelli F; De Santis R
Oncotarget; 2017 Apr; 8(14):22590-22605. PubMed ID: 28186982
[TBL] [Abstract][Full Text] [Related]
8. Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models.
Hapuarachchige S; Kato Y; Artemov D
Sci Rep; 2016 Apr; 6():24298. PubMed ID: 27068794
[TBL] [Abstract][Full Text] [Related]
9. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
[TBL] [Abstract][Full Text] [Related]
10. Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm.
Albertoni C; Leoni B; Rosi A; D'Alessio V; Carollo V; Spagnoli LG; van Echteld C; De Santis R
Cancer Biother Radiopharm; 2015 Sep; 30(7):291-8. PubMed ID: 26167947
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeling of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with biotinylated F-18 prosthetic groups and imaging of their delivery to the brain with positron emission tomography.
Sirianni RW; Zheng MQ; Patel TR; Shafbauer T; Zhou J; Saltzman WM; Carson RE; Huang Y
Bioconjug Chem; 2014 Dec; 25(12):2157-65. PubMed ID: 25322194
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab.
De Santis R; Rosi A; Anastasi AM; Chiapparino C; Albertoni C; Leoni B; Pelliccia A; Santapaola D; Carollo V; Marra E; Aurisicchio L; Arseni B; Pacello ML; Palmieri G; Battella S; Petronzelli F; Milazzo FM
Oncotarget; 2014 Oct; 5(19):9239-55. PubMed ID: 25238453
[TBL] [Abstract][Full Text] [Related]
13. Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.
Botta F; Cremonesi M; Ferrari ME; Amato E; Guerriero F; Vavassori A; Sarnelli A; Severi S; Pedroli G; Paganelli G
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1047-56. PubMed ID: 23640466
[TBL] [Abstract][Full Text] [Related]
14. IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin.
Paganelli G; De Cicco C; Ferrari ME; McVie G; Pagani G; Leonardi MC; Cremonesi M; Ferrari A; Pacifici M; Di Dia A; Botta F; De Santis R; Galimberti V; Luini A; Orecchia R; Veronesi U
Ecancermedicalscience; 2010; 4():166. PubMed ID: 22276027
[TBL] [Abstract][Full Text] [Related]
15. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
[TBL] [Abstract][Full Text] [Related]
16. Chemical linkage to injected tissues is a distinctive property of oxidized avidin.
De Santis R; Anastasi AM; Pelliccia A; Rosi A; Albertoni C; Verdoliva A; Petronzelli F; D'Alessio V; Serani S; Nuzzolo CA
PLoS One; 2011; 6(6):e21075. PubMed ID: 21701578
[TBL] [Abstract][Full Text] [Related]
17. Pretargeted radioimmunotherapy for hematologic and other malignancies.
Walter RB; Press OW; Pagel JM
Cancer Biother Radiopharm; 2010 Apr; 25(2):125-42. PubMed ID: 20423225
[TBL] [Abstract][Full Text] [Related]
18. Challenging semi-bootstrapping molecular-replacement strategy reveals intriguing crystal packing of rhizavidin.
Meir A; Livnah O
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Apr; 66(Pt 4):373-8. PubMed ID: 20383003
[TBL] [Abstract][Full Text] [Related]
19. OXavidin for tissue targeting biotinylated therapeutics.
De Santis R; Albertoni C; Rosi A; Leoni B; Petronzelli F; D'Alessio V; Nucera E; Salvatori G; Paganelli G; Verdoliva A; Carminati P; Nuzzolo CA
J Biomed Biotechnol; 2009; 2009():921434. PubMed ID: 20130784
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties.
Verdoliva A; Bellofiore P; Rivieccio V; Catello S; Colombo M; Albertoni C; Rosi A; Leoni B; Anastasi AM; De Santis R
J Biol Chem; 2010 Mar; 285(12):9090-9. PubMed ID: 20100839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
